相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy (vol 13, pg 273, 2016)
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Michael S. Goldberg
CELL (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
Eoin F. McKinney et al.
NATURE (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
T-cell exhaustion in the tumor microenvironment
Y. Jiang et al.
CELL DEATH & DISEASE (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells
Matthias Woelfl et al.
NATURE PROTOCOLS (2014)
Localized Immunotherapy via Liposome-Anchored Anti-CD137+IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Brandon Kwong et al.
CANCER RESEARCH (2013)
Applications of nanotechnology for immunology
Douglas M. Smith et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Joannes F. M. Jacobs et al.
LANCET ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
Brandon Kwong et al.
BIOMATERIALS (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Thiol-click chemistry: a multifaceted toolbox for small molecule and polymer synthesis
Charles E. Hoyle et al.
CHEMICAL SOCIETY REVIEWS (2010)
Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice
Michael J. Gough et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery
Jianjun Cheng et al.
BIOMATERIALS (2007)
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
K Sugamura et al.
NATURE REVIEWS IMMUNOLOGY (2004)
分享论文
